FATE THERAPEUTICS INC Subsidiaries
Every subsidiary the company listed in Exhibit 21 of its annual reports, newest list first (3 lists). Names and jurisdictions are as filed.
- 2023-02-28: Subsidiary Fate Therapeutics (UK) Ltd.; Jurisdiction Fate Therapeutics (UK) Ltd..
- 2023-02-28: Subsidiary Tfinity Therapeutics, Inc.; Jurisdiction Tfinity Therapeutics, Inc..
- 2023-02-28: Subsidiary Fate Therapeutics B.V.; Jurisdiction Fate Therapeutics B.V..
- 2023-02-28: Subsidiary Senescea Therapeutics, Inc.; Jurisdiction Senescea Therapeutics, Inc..
| Annual report filed | Subsidiary | Jurisdiction |
|---|
| 2023-02-28 | Fate Therapeutics (UK) Ltd. | Fate Therapeutics (UK) Ltd. |
|---|
| 2023-02-28 | Tfinity Therapeutics, Inc. | Tfinity Therapeutics, Inc. |
|---|
| 2023-02-28 | Fate Therapeutics B.V. | Fate Therapeutics B.V. |
|---|
| 2023-02-28 | Senescea Therapeutics, Inc. | Senescea Therapeutics, Inc. |
|---|
| 2019-03-05 | Fate Therapeutics (UK) Ltd. | Fate Therapeutics (UK) Ltd. |
|---|
| 2019-03-05 | Tfinity Therapeutics, Inc. | Tfinity Therapeutics, Inc. |
|---|
| 2019-03-05 | Fate Therapeutics B.V. | Fate Therapeutics B.V. |
|---|
| 2017-03-16 | Fate Therapeutics (UK) Ltd. | Fate Therapeutics (UK) Ltd. |
|---|
| 2017-03-16 | Tfinity Therapeutics, Inc. | Tfinity Therapeutics, Inc. |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
|---|
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
|---|